source
- FDA approves Roivant's new dermatomyositis therapyThe FDA has granted approval to a therapy developed by Roivant for the treatment of dermatomyositis, a rare autoimmune condition that causes muscle inflammation and skin rash. The decision adds a…
- Priovant nabs first FDA approval for targeted tablet in dermatomyositisLisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with the rare autoimmune disease, setting up the drug for blockbuster status…BioSpace · 1h ago↗ source